erdosteine 300mg capsules (Erdotin)

Advice

Following a full submission

erdosteine (Erdotin®) is not recommended for use within NHS Scotland as an expectorant for the symptomatic treatment of acute exacerbations of chronic bronchitis in adults.

Evidence for the clinical efficacy of erdosteine is limited and was obtained from studies that do not reflect current practice for the management of chronic obstructive pulmonary disease (COPD) in NHS Scotland. The manufacturer did not present a sufficiently robust clinical or economic case for erdosteine to gain acceptance by SMC.